NCT06061926

Effect of Celery Seed on the Components of Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion

Effect of Celery Seed (Apium Graveolens L.) Administration on the Components of Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion
University of Guadalajara·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov
Study focus
Disease/Condition
Metabolic Syndrome
Drug/Device/Intervention
Celery Seed
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
University of Guadalajara
Location
Guadalajara, Mexico
Timeline & enrollment
Phase
Phase 2
Start date
May 20, 2023
End date
Dec 01, 2025
Enrollment
28 participants
Primary outcome

Waist Circumference (WC),Systolic Blood Pressure (SBP),Diastolic Blood Pressure (DBP),High-Density Lipoprotein (HDL-c),Fasting Blood Triglycerides Concentration (TG),Fasting Serum Glucose (FSG),Insulin Sensitivity (Matsuda Index),Total Insulin Secretion,First Phase of Insuline Secretion (Stumvoll Index)

Summary

The Metabolic Syndrome (MS) is a cluster of cardiometabolic risk factors, which include
 abdominal obesity, hyperglycemia, dyslipidemia, and high blood pressure. MS is a global
 health problem, it represents a risk factor for the progression of cardiovascular disease,
 entitie that constitute the main cause of mortality in the world and in Mexico. The current
 treatment involves lifestyle changes and pharmacological treatment for each of the components
 of MS, however, there is no single approved treatment to control all components. Celery seed
 (Apium graveolens L.) from the Apiaceae family contains the flavonoids apigenin and luteolin;
 essential oils such as d-limonene, selinene and phthalides such as 3-n-butylphthalide. Thanks
 to its bioactive components, celery seed has proven to be effective in treating individual MS
 disorders; however, most studies are in animal models and there are no clinical studies that
 evaluate its effectiveness on all components of the system. MS, insulin sensitivity and
 insulin secretion so it could appear as a new, safe and effective complementary therapy for
 the treatment of MS.
 
 The aim of this study is to evaluate the effect of celery seed on the components of metabolic
 syndrome, insulin sensitivity, and insulin secretion.

ICD-10 classifications
Metabolic disordersMetabolic disorder, unspecifiedOther metabolic disordersOther specified metabolic disordersNutritional and metabolic disorders in diseases classified elsewhere
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06061926
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06061926 through Pure Global AI's free database. This Phase 2 trial is sponsored by University of Guadalajara and is currently Recruiting. The study focuses on Metabolic Syndrome. Target enrollment is 28 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.